Why ACOG and CDC Moved the GBS Culture Window to 36–37 Weeks
For more than two decades, the standard for prenatal Group B Streptococcus (GBS) colonization screening was a vaginal–rectal culture at 35–37 weeks of gestation. In 2019, the American College of Obstetricians and Gynecologists (ACOG) replaced its older Committee Opinion with Committee Opinion 797, aligning with the Centers for Disease Control and Prevention (CDC) recommendation to perform screening at 36 0/7 weeks through 37 6/7 weeks. The reason is technical but consequential: culture results predict colonization status at delivery best when the swab is collected within five weeks of birth. After approximately 5 weeks, the negative predictive value of the swab declines, which means a 'negative' result drawn too early can miss colonization that develops or rises closer to term. Narrowing the window standardizes how clinicians act on those cultures and reduces the probability of a false-negative gating intrapartum decisions. The change does not alter the indication itself — every pregnant person without an indication for empiric intrapartum prophylaxis (such as GBS bacteriuria in the current pregnancy or a previous infant with invasive GBS disease) should still be offered routine screening. It simply moves the timing forward by one week to capture the colonization status that actually matters: the one that exists when the baby is born.
A practical implication for the prenatal calendar: most patients receive their group B strep swab at the same visit as the third-trimester anatomy review and Tdap administration, so a single visit around 36 weeks now covers vaccine timing, screening, and birth-plan discussion. Patients planning a home birth or birth-center delivery should explicitly confirm that the screening was performed and that results will be available to the receiving labor team, since transfer to a hospital is the scenario in which knowing colonization status matters most. Patients with a previously negative culture in the current pregnancy who present in labor more than five weeks after the swab should be treated as if the status is unknown if any clinical risk factor is present.
What Intrapartum Antibiotic Prophylaxis Actually Prevents — and What It Does Not
Intrapartum antibiotic prophylaxis (IAP) targets early-onset neonatal GBS disease, defined by the CDC as invasive GBS infection (sepsis, pneumonia, meningitis) in the first 0–6 days of life. Before universal screening and IAP, early-onset GBS disease occurred at roughly 1.7 cases per 1,000 live births in the United States. After universal screening and IAP became standard, early-onset rates fell to roughly 0.2–0.25 per 1,000 — an approximately 80% reduction. IAP does not prevent late-onset GBS disease (days 7–89), which has remained stable at roughly 0.3 per 1,000 because that disease pathway involves postnatal acquisition and host immune factors that prenatal cultures cannot influence. The first-line agent is intravenous penicillin G; ampicillin is acceptable. For low-risk penicillin allergy (rash without anaphylaxis), cefazolin is used. For high-risk allergy with confirmed clindamycin susceptibility, clindamycin is acceptable. When susceptibility is unknown or resistance is documented, vancomycin is the back-stop. Importantly, the first dose should be given at least four hours before delivery for full benefit; shorter durations still reduce risk but less robustly. Oral antibiotics during pregnancy are not a substitute — colonization recurs and the protective effect of IAP is generated by adequate blood levels at the moment the baby transits the colonized canal.
Late-onset GBS disease is the part of this conversation that often gets compressed in counseling. While intrapartum antibiotics dramatically reduce early-onset infection in the first week, infants in the 1-to-3-month range can still develop GBS meningitis through postnatal acquisition pathways that screening cannot influence. Parents should know that a normal newborn period does not eliminate the small ongoing risk and that any unexplained fever, poor feeding, or lethargy in this age window warrants prompt pediatric evaluation. This is not a reason to be vigilant in a way that distorts daily life — overall rates remain low — but it is a reason to take the standard 'first fever under 90 days' rule seriously rather than treat it as administrative caution.
Who Is Screened, Who Skips Screening, and Why
The CDC and ACOG specify a small set of clinical situations in which screening is unnecessary because IAP is indicated empirically regardless of culture result. These include any GBS bacteriuria at any concentration in the current pregnancy and a previous infant with invasive GBS disease. In both cases, the pregnant person is treated as colonized and receives IAP in labor without re-culturing at 36–37 weeks. For everyone else without a known allergy contraindicating standard prophylaxis, the 36 0/7 – 37 6/7 week swab is the basis for intrapartum decision-making. A positive culture triggers IAP at the onset of labor or rupture of membranes. A negative culture, by contrast, does not provide blanket protection: the CDC continues to recommend IAP in unknown-status patients who present at less than 37 weeks gestation, have rupture of membranes ≥18 hours, or develop intrapartum fever ≥38.0°C (100.4°F). Planned cesarean delivery before labor and before rupture of membranes is the major exception — in this scenario, vertical transmission risk is minimal and GBS-specific IAP is not given (although standard surgical prophylaxis is still required). This nuance — that the negative culture is only as good as its timing and the clinical scenario in which it is being applied — is one of the most common sources of avoidable counseling errors at the bedside.
One scenario that confuses both clinicians and patients is the negative culture that arrives accompanied by an intrapartum fever. The CDC explicitly classifies this as a situation requiring IAP, because intrapartum fever can mark chorioamnionitis or another infectious process for which GBS coverage is appropriate even when colonization was not detected at 36 weeks. Patients sometimes interpret this as 'they're treating me as if I had it after all,' which can feel inconsistent. The clearer framing: IAP is not solely about GBS status — it is about cumulative risk at the moment of delivery, and the culture is one input among several. Documenting allergies and prior antibiotic exposures helps the labor team make the correct empiric choice when fever appears.
The Nucleic Acid Amplification Test (NAAT) Question and Self-Collection
Most U.S. obstetric units still perform conventional vaginal–rectal culture as the primary screening tool, but intrapartum NAAT — a rapid molecular test — has been studied and is sometimes used for unknown-status patients in labor. NAAT is highly sensitive and specific compared with same-time culture, but its operational advantage (results in roughly 1 hour) comes with caveats: the assay must be available 24/7 in a facility with skilled microbiology support, and a negative intrapartum NAAT in an unknown-status patient does not override clinical risk factors such as fever or prolonged rupture of membranes. ACOG explicitly notes that intrapartum NAAT does not replace the recommended antepartum culture-based screening, in part because antepartum colonization status drives downstream decisions like timing of arrival at labor and delivery, anesthesia planning, and antibiotic preparation. Self-collection of the vaginal–rectal swab is acceptable when proper instructions are provided; data show comparable sensitivity to clinician-collected swabs and the practice can reduce barriers to screening. The key is that the swab must include both vaginal and rectal sampling — rectal-only or vaginal-only swabs significantly under-detect colonization because GBS is part of the lower GI flora and can colonize the vagina intermittently.
When NAAT is used as a back-up for unknown status at presentation, parents sometimes ask whether they can request it instead of the antepartum culture. The short answer is no in most U.S. settings — the antepartum culture is the recommended program and intrapartum NAAT is reserved for specific scenarios. The longer answer is that culture-based screening is the more robust system when the entire downstream workflow is designed around it. Self-collection is a useful patient-empowerment tool, but a poorly performed self-collection that misses the rectal site can produce a false-negative result with serious downstream consequences. Patients opting for self-collection should request a clear illustration or instruction from the clinic and confirm that both vaginal and rectal sampling are included.
What Parents Should Ask Their OB Between Now and Delivery
Three questions reliably surface gaps in counseling. First: when is my GBS culture being drawn, and what is the plan if I deliver before that date? If a patient is at higher risk for preterm labor, clinicians may modify timing or have a low threshold for empiric IAP. Second: do I have any indication for empiric IAP regardless of culture (GBS bacteriuria this pregnancy, previous infant with invasive GBS, or planned management before culture is available)? Confirming this on the prenatal record prevents miscommunication on the labor floor when documentation is rushed. Third: if I am penicillin allergic, what is my allergy classification and which agent will be used? Many patients carry a 'penicillin allergy' label from childhood that, on careful history, represents a low-risk reaction; an allergy clarification visit before delivery can preserve first-line therapy and reduces use of broader-spectrum agents like vancomycin. The Wermom Health editorial team consistently sees these three questions reduce day-of-delivery confusion and improve the likelihood that a colonized patient receives adequately dosed, adequately timed intrapartum coverage — which is what the entire screening program is designed to deliver.
Finally, a counseling point about postpartum follow-up: patients sometimes carry forward a misimpression that having received IAP means their baby has been treated for GBS and no further attention is needed. The reality is that IAP is a prophylactic intervention, not a treatment, and the baby's own clinical course in the first 48 hours remains the most important data point. Nurseries follow specific observation protocols based on duration of IAP exposure, gestational age, and presence of any signs of illness — and parents are well-served by understanding why their infant may be observed for slightly longer in the hospital after a positive maternal screen even when everything appears entirely normal.